Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

Stock Information for Oramed Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oramed Pharmaceuticals Inc.

Oramed Reports Fiscal Third Quarter 2025 Financial Results
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
Oramed Pharmaceuticals Issues Letter to Shareholders
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
Oramed Letter to Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.